To report 11 cases of possible erythromycin-induced hearing loss and to review all cases reported in the literature.
CASE SUMMARY:
In the 11 cases reported, the following are reviewed: Age, gender, time to onset of and recovery from hypoacusis in relation to erythromycin administration, presence or absence of renal or hepatic disease, underlying disorders, and concurrent administration of other drugs. Hypoacusis appeared with dosages equal to or higher than 4 g/d in patients with a mean age of 52.5 ± 19 years, a high percentage of whom (45 percent) presented with renal impairment. The hearing loss was reversible in all cases, and subsided a few days (median=3) after dosage reduction or drug discontinuation.
DISCUSSION:
Our patients' characteristics are similar to those of patients reported in the literature. Most data indicate that erythromycin-induced hypoacusis is a dose-dependent effect; however, its occurrence in patients otherwise free from disposing factors suggests that it is idiosyncratic.
CONCLUSIONS:
Erythromycin administered for appropriate indications and dosage adjustments in patients with impaired renal and/or liver function may prevent or reduce the incidence of erythromycin-induced hypoacusis.
Get full access to this article
View all access options for this article.
References
1.
SteigbigelNH. Erythromycin, lincomycin, and clindamycin. In: MandellGLDouglasRGJrBennettJE, eds. Principles and practices of infectious diseases. 3rd ed.New York: John Wiley, 1990:308–17.
2.
PeritiPMazzeiTMiniENovelliA. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (part I). Clin Pharmacokinet1989; 16:193–214.
3.
KuninCM. A guide to use of antibiotics in patients with renal disease. Ann Intern Med1967; 67:151–8.
4.
MintzUAmirJPinkhasJde VriesA. Transient perceptive deafness due to erythromycin lactobionate. JAMA1973; 225:1122–3.
5.
BrummettREFoxKE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother1989; 33:791–6.
6.
SacristánJASotoJde CosMA. Erythromycin-induced hearing loss (letter). Lancet1990; 2:1080.
7.
KarmodyCSWeinsteinL. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate. Ann Otol Rhinol Laryngol1977; 86:9–11.
8.
KanferADanielFVigeralEMeryJP. Erythromycin ototoxicity in patients with renal insufficiency. Therapie1980; 35:365–7.
9.
EckmanMRJohnsonTRiesR. Partial deafness after erythromycin (letter). N Engl J Med1975; 292:649.
10.
QuinnanGVMcCabeWR. Ototoxicity of erythromycin (letter). Lancet1978; 2:1160–1.
11.
Van MarionWFvan der MeerJWMKalefMWSchichtSM. Ototoxicity of erythromycin (letter). Lancet1978; 2:214–5.
12.
MeryJPKanferA. Ototoxicity of erythromycin in patients with renal insufficiency (letter). N Engl J Med1979; 301:944.
13.
LornoyWSteyaertJ. Ototoxicity of erythromycin lactobionate (letter). Acta Clin Belg1979; 34:111.
ErrickJKHyrciuk-FlaskaLThiesH. Probable erythromycin ototoxicity. Drug Intell Clin Pharm1980; 14:623–5.
16.
BecknerRRGantzNHughesJPFaricyJP. Ototoxicity of erythromycin glucepate. Am J Obstet Gynecol1981; 139:738–9.
17.
TaylorRSchofieldISRamosJMBintAJWardMK. Ototoxicity of erythromycin in peritoneal dialysis patients. Lancet1981; 2:935–6.
18.
MillerSM. Erythromycin ototoxicity. Med J Aust1982; 2:242–3.
19.
MeryJPKanferA. Alterations in pharmacokinetics and ototoxicity of erythromycin in renal failure (letter). Am J Kidney Dis1984; 4:95.
20.
SchwartzJIMagginiGA. Erythromycin-induced ototoxicity substained by rechallenge. Clin Pharm1982; 1:374–6.
21.
HaydonRCThelinJWDavisWE. Erythromycin ototoxicity: Analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg1984; 92:678–84.
22.
KrobothPDMcNeilMAKreegerADomínguezJRaultL. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. Arch Intern Med1983; 143:1263–5.
23.
DemaldentJERollandAMongrolleY. Potential ototoxicity of erythromycin. Ann Otolaryngol Chir Cervicofac1984; 101:643–7.
24.
RydbergJ. Reversible hearing loss and erythromycin (letter). Lakartidningen1984; 81:1308.
25.
SchweitzerVGOlsonNR. Ototoxic effect of erythromycin therapy. Arch Otolaryngol1984; 110:258–60.
26.
KoegelLJr. Ototoxicity: A contemporary review of aminoglycosides, loop diuretics, acetylsalicylic acid, quinine, erythromycin, and cisplatinum. Am J Otol1985; 6:190–9.
27.
LevinGBehrenthE. Irreversible ototoxic effect of erythromycin. Scand Audiol1986; 15:41–2.
28.
UmsteadGSNeumannKH. Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction. Arch Intern Med1986; 146:897–9.
29.
DylewskiJ. Irreversible sensorineural hearing loss due to erythromycin. Can Med Assoc J1988; 139:230–1.
30.
MartíJMutioLAlonsoAAltunaEBustilloJM. Hipoacusia neurosensorial reversible secundaria a eritromicina. An Otorrinolaringol Ibero Am1988; 15:429–32.
31.
RelloJCasesC GarcíaTriginerCNetA. Ototoxicidad por lactobionato de eritromicina. Med Intensiv1989; 13:249–50.
32.
AgustíCFerránFGeaJPicadoC. Ototoxic reaction to erythromycin (letter). Arch Intern Med1991; 151:380.
33.
KempEKeidarSBrookJG. Sensorineural hearing loss with low dose erythromycin (letter). BMJ1991; 302:1341.
34.
WhitenerCJParkerJELappNL. Erythromycin ototoxicity: A call to heighten recognition. South Med J1991; 84:1214–6.
35.
SacristánJAde CosMASotoJZurbanoFPascualJTasisA. Ototoxicity of erythromycin in man: Electrophysiological approach. Am J Otol1993; 14:186–8.
36.
CramerR. Erythromycin ototoxicity. Drug Intell Clin Pharm1986; 20: 764–5.
37.
SwansonDJSunggRJFineMJOrloffJJChuSYYuV. Erythromycin ototoxicity: Prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med1992; 92:61–8.
38.
AustinKLMatherLEPhilpotCRMcDonaldPJ. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol1980; 10:273–9.
39.
GordonRCRegameyCKirbyWMM. Serum protein binding of erythromycin, lincomycin and clindamycin. J Pharm Sci1973; 62: 1074–7.
40.
BerganTEngesetAOlszewkiW. Does serum protein binding inhibit tissue penetration of antibiotics?. Rev Infect Dis1987; 9:713–8.
41.
BarreJMallatARosenbaumJDeforgesLHouinGDhumeauxD. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol1987; 23:753–7.
42.
ZiniRRiantPBarréJTillementJP. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (part II). Clin Pharmacokinet1990; 19:218–29.
43.
HuangMYSchachtJ. Drug-induced ototoxicity. Pathogenesis and prevention. Med Toxicol Adverse Drug Exp1989; 4:452–67.
44.
StuppHFKupperKLaglerFSousHQuateM. Inner ear concentration and ototoxicity of different antibiotics in local and systemic application. Audiology1973; 12:350–63.
45.
BrummettREJacksonRT. Age related changes influencing the effects of drugs and other xenobiotics on sensorineural hearing. Pharmacol Ther1984; 26:209–19.
